Barry Berkowitz, Phd Email and Phone Number
Barry Berkowitz, Phd work email
- Valid
- Valid
- Valid
- Valid
Barry Berkowitz, Phd personal email
Founded, built, and led highly successful drug discovery and development organizations in start up and large pharmaceutical environments. Built value around both service and product focused companies. Led groups and companies several of which I co-founded, through product development and numerous strategic transactions, including alliances with major pharma companies, such as Eli Lilly, Pfizer, Wyeth, and Bristol Myers Squibb, as well as M&A. Track record of identifying and developing outstanding talent, technology, and product opportunities. A number of my key hires and students have become scientific, corporate and industry leaders. Adjunct Professor at Boston University Medical School and Northeastern University School of Pharmacy. Co-inventor on more than 15 patents and current applications. Over 125 peer-reviewed publications.
Northeastern University, Bouvé College Of Health Sciences
View- Employees:
- 149
-
Adjunct ProfessorNortheastern University, Bouvé College Of Health SciencesFramingham, Ma, Us
-
Co-Founder, Chairman Of The Board, President, And CeoBessor Pharma 2010 - PresentBessor Pharma is utilizing an innovative technology and business model for new drug development and value creation, with a focus on translating opportunities from university laboratories into proof-of-concept or clinical-ready packages for the pharma/biotech industry. The Company, which has unique skills, connectivity, and capital markets sophistication, is forging an ecosystem of academic and industry partners as key stakeholders facilitating translational R&D. Bessor is differentiated by its: aligned team with an unparalleled track record in drug development; operational progress; and unique collaborative partnerships fueling an innovative pipeline of highly needed drugs.We have built a highly experienced and engaged leadership team and advisors that are committed to the translational development of our projects. Collectively, our team and advisors have been instrumental in the development of nearly 20 marketed drugs, including: Tykerb® (lapatinib), Gemzar® (gemcitabine), Coreg™ (carvedilol), and Corlopam® (fenoldopam).http://bessorpharma.com/
-
Adjunct ProfessorNortheastern University, Bouvé College Of Health Sciences 2006 - PresentBoston -
Adjunct Professor Of Pharmacology And Experimental TherapeuticsBoston University School Of Medicine 1998 - Present -
President And CeoCetek Corporation 2005 - 2007Evolved company from research to R&D organization focused on novel methods and analytical tools for screening towards the discovery and development of cancer therapeutics and antivirals. Positioned company for financing/liquidity event. Assets sold to big pharma. -
President And CeoScion Pharmaceuticals 2004 - 2005Hired to assist in liquidating company, which was a higher throughput cell screening and drug development company using electrophysiology. Assets sold to big pharma.
-
Founder, Chairman Of The Board Of Directors, And CeoNew Chemical Entities, Inc. (Acquired By Albany Molecular Research, Inc.) 1997 - 2004Founded drug discovery and chemistry-focused drug service company. Organized company, developed strategy, secured venture financing (MVM, BioVentures/Marc Goldberg), sold company to Albany Molecular Research, Inc. (AMRI) in January 2001 for 4X return on investment. After sale, served as AMRI’s Corporate Vice President, reporting directly to CEO, leading key projects and high value business development efforts, including compound alliances with several companies, including Eli Lilly and Bristol Myers Squibb (BMS).
-
Co-Founder, President, And CeoMyco/Chemgenics Pharmaceuticals (Merged With Millennium Pharmaceuticals) 1992 - 1997Co-Founded (with Dr. Gerry Fink, Director of Whitehead Institute)Drug discovery and functional genomics company that combined molecular biology and natural product drug sources with high throughput screening. Built organization, developed strategy, raised venture financing (Bessemer, TL Ventures), and established major alliances for anti-infective directed technologies and drugs with Pfizer and Wyeth. Merged company with Millennium Pharmaceuticals in 1997 in $90 million stock transaction (Myco/ChemGenics stockholders received 25% of the outstanding stock of Millennium Pharmaceuticals). Key hires included Alan Crane (Former CEO, Tempo Pharmaceuticals, ex-CEO Momenta Pharmaceuticals, General Partner Polaris Ventures).
-
Co-Founder And Ceo (Strong Pharmaceuticals Now Fibrogen)Fibrogen, Inc. 1992 - 1993Co-founded company with Prof. Darwin Prockop to develop recombinant human collagen and to affect the collagen bio-synthetic pathway in order to treat and prevent fibrosis. Tom Neff and colleagues invested in company and later changed the name of Strong Pharmaceuticals to Fibrogen (NASDAQ:FGEN). -
Founder, President, And CeoMagainin Sciences Inc. (Ipo 1991) 1988 - 1992Led, developed, and implemented overall company business and scientific strategy for new class of anti-infectives and host defense drugs. Chairman of the Board (1991-1992).
-
Vice President, Compound Acquisitions And Development (Worldwide)Smith Kline & French Labs 1986 - 1988Responsible for Departments of Project Management, Strategic Analysis and Planning, Compound Acquisitions and Technologies on a worldwide basis. Member of team that acquired Carvedalol. Built acquisitions division. Served as member R&D Executive Committee, which was responsible for decisions on biology, pharmacology, chemistry, pathology/toxicology, and clinical matters of drug discovery process in U.S. (1983-1987).
-
Vice President, Biological Sciences And Biopharmaceutical Research & DevelopmentSmith Kline & French Labs 1985 - 1986Responsible for drug discovery in biological sciences area (Pharmacology, Molecular Pharmacology, Cancer (developed Topotecan), Immunology and Anti-infective Therapeutics, Vaccines) and discovery and development of biopharmaceutical products.Co-Chairman of Operating Committee for Programs, the key world-wide decision making and coordinating body for all biological and chemical research and development programs.
-
Director Of PharmacologySmith Kline & French Labs 1979 - 1983Responsible for all SK&F pharmacology in the U.S.
-
Associate Member (1976-1979); Assistant Member (1971-1976); Post-Doctoral Fellow (1968-1970)Roche Institute Of Molecular Biology 1968 - 1979As Assistant and Associate Member, directed pharmacology laboratory with research interests in compounds to treat pain, narcotic analgesics, immunopharmacology of analgesics, CNS Pharmacology, and antagonists, biogenic amines, and molecular mechanics of cardiovascular drugs. Selected, trained, and supervised one graduate student (Ph.D. received) and five post-doctoral Fellows
Barry Berkowitz, Phd Education Details
-
Pharmacology -
B.S. (Pharmacy) With High Honor
-
Roche Institute Of Molecular BiologyImmuno-Pharmacology Focus
Frequently Asked Questions about Barry Berkowitz, Phd
What company does Barry Berkowitz, Phd work for?
Barry Berkowitz, Phd works for Northeastern University, Bouvé College Of Health Sciences
What is Barry Berkowitz, Phd's role at the current company?
Barry Berkowitz, Phd's current role is Adjunct Professor.
What is Barry Berkowitz, Phd's email address?
Barry Berkowitz, Phd's email address is be****@****gen.com
What schools did Barry Berkowitz, Phd attend?
Barry Berkowitz, Phd attended University Of California, San Francisco, Northeastern University, Roche Institute Of Molecular Biology.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial